ResMed's Moat Is Underpinned by Switching Costs and Intangible Brand Assets
Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...
ResMed targets 59-60% gross margins and expanded global reach for AirSense 11
Q2 2025 Management View CEO Michael Farrell reported 10% global revenue growth, driven by demand across the sleep health, ...
ResMed: Digital Health Drives Q2 Growth
ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth ...
ResMed beats quarterly profit estimates on demand for sleep disorder devices
ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder.
Sleep Software Market to Hit USD 1,569.2 Million by 2030 with 10.1% CAGR | MarketsandMarkets™
The global sleep software market valued at US$ 776.2 Million in 2023, is forecasted to grow at a robust CAGR of 10.1%, ...
What Is A 'Morning Shed' Routine, And Does It Actually Work?
Or could those jumping on the morning shed trend actually sabotage their beauty goals? We spoke to dermatologists and hair ...
FDA approves medication for sleep apnea
The U.S. Food and Drug Administration calls Zepbound the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity. The approval supports evidence ...